Evidence map›Paper›PMID 29861805›Full record

ArticlePain research & management2018

Elevated Levels of Eotaxin-2 in Serum of Fibromyalgia Patients.

Victoria Furer, Eyal Hazan, Adi Mor, Michal Segal, Avi Katav, Valerie Aloush, Ori Elkayam, Jacob George, Jacob N Ablin

Open access · goldAbstract read
In one paragraph

Article in Pain research & management, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Victoria FurerTel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0001-5193-4207
Eyal HazanTel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Adi MorChemomAb Ltd., Tel Aviv, Israel.
Michal SegalChemomAb Ltd., Tel Aviv, Israel.
Avi KatavChemomAb Ltd., Tel Aviv, Israel.
Valerie AloushTel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Ori ElkayamTel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Jacob GeorgeChemomAb Ltd., Tel Aviv, Israel.
Jacob N AblinTel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Tel Aviv University · ILTel Aviv Sourasky Medical Center · ILKaplan Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FMS patients demonstrate an altered profile of chemokines relative to healthy controls (HC). Eotaxin-2 is a potent chemoattractant distributed in a variety of tissues. The aim of the study was to compare serum levels of eotaxin-2 between FMS patients and HC and to examine a potential correlation between eotaxin-2 levels and clinical parameters of FMS.

Indexed as

AdultChemokine CCL24Cohort StudiesC-Reactive ProteinFemaleFibromyalgiaHumansMaleMiddle AgedPain MeasurementPsychiatric Status Rating ScalesYoung AdultChemokine CCL24C-Reactive Protein

Identifiers

PMID29861805
PMCPMC5971249
OpenAlexW2800225382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.